130 related articles for article (PubMed ID: 23241050)
1. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
2. Demographic characterization of Brazilian patients enrolled in the Fabry Registry.
Martins AM; Kyosen SO; Garrote J; Marques FM; Guilhem JG; Macedo E; Sobral Neto J; Ura S
Genet Mol Res; 2013 Jan; 12(1):136-42. PubMed ID: 23408399
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
[TBL] [Abstract][Full Text] [Related]
4. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic events in Fabry disease and the impact of factor V Leiden.
Lenders M; Karabul N; Duning T; Schmitz B; Schelleckes M; Mesters R; Hense HW; Beck M; Brand SM; Brand E
Neurology; 2015 Mar; 84(10):1009-16. PubMed ID: 25663229
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
7. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
Barba-Romero MÁ; Pintos-Morell G
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
[TBL] [Abstract][Full Text] [Related]
9. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
12. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
Terryn W; Cochat P; Froissart R; Ortiz A; Pirson Y; Poppe B; Serra A; Van Biesen W; Vanholder R; Wanner C
Nephrol Dial Transplant; 2013 Mar; 28(3):505-17. PubMed ID: 23234755
[TBL] [Abstract][Full Text] [Related]
13. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
14. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.
Sirrs S; Clarke JT; Bichet DG; Casey R; Lemoine K; Flowerdew G; Sinasac DS; West ML
Mol Genet Metab; 2010 Apr; 99(4):367-73. PubMed ID: 20022777
[TBL] [Abstract][Full Text] [Related]
15. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of patients from a Spanish Registry of Fabry disease in two periods].
Barba Romero MÁ; Rivera Gallego A; Pintos Morell G;
Med Clin (Barc); 2012 Oct; 139(9):379-84. PubMed ID: 22266083
[TBL] [Abstract][Full Text] [Related]
17. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
18. Fabry in the older patient: Clinical consequences and possibilities for treatment.
Lidove O; Barbey F; Niu DM; Brand E; Nicholls K; Bizjajeva S; Hughes DA
Mol Genet Metab; 2016 Aug; 118(4):319-25. PubMed ID: 27221354
[TBL] [Abstract][Full Text] [Related]
19. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease.
Avarappattu J; Gaspert A; Spartà G; Rohrbach M
Pediatr Nephrol; 2024 Jan; 39(1):131-140. PubMed ID: 37470867
[TBL] [Abstract][Full Text] [Related]
20. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.
Wanner C; Ortiz A; Wilcox WR; Hopkin RJ; Johnson J; Ponce E; Ebels JT; Batista JL; Maski M; Politei JM; Martins AM; Banikazemi M; Linhart A; Mauer M; Oliveira JP; Weidemann F; Germain DP
Mol Genet Metab; 2023 Jul; 139(3):107603. PubMed ID: 37236007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
